Arecor Therapeutics PLC Arecor to present on Investor Meet Company
27 September 2024 - 4:00PM
RNS Non-Regulatory
RNS Number : 9019F
Arecor Therapeutics PLC
27 September 2024
Arecor Therapeutics
plc
("Arecor"
or the "Group")
Arecor to
present on Investor Meet Company platform
Cambridge, UK, 27 September 2024:
Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable
healthier lives, today announces
that Sarah Howell, Chief Executive Officer, will
be providing a live presentation of the Group's recently announced
interim results for the six months ended 30 June 2024 via the
Investor Meet Company platform, on Thursday 3 October at 3pm
BST.
The presentation is open to all
existing and potential shareholders and will be followed by a
Q&A session. Questions can be submitted ahead of the event
through the Investor Meet Company dashboard up until 9am BST on
Wednesday 2 October 2024, or at any time during the live
presentation.
To sign up to Investor Meet Company
for free and to register for Arecor's presentation, please
visit:
https://www.investormeetcompany.com/companies/arecor-therapeutics-plc
Investors who already follow Arecor
on the Investor Meet Company platform will automatically be invited
to the event.
-ENDS-
For
more information, please contact:
|
Arecor Therapeutics plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Panmure Liberum Limited (NOMAD and Joint
Broker)
|
|
|
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate
Broking)
|
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
WG
Partners LLP (Joint Broker)
|
|
|
Nigel Barnes, Satheesh
Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0)203 705 9321
|
|
|
|
|
ICR
Consilium
|
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com
|
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a
globally focused biopharmaceutical company transforming patient
care by bringing innovative medicines to market through the
enhancement of existing therapeutic products. By applying our
innovative proprietary technology platform, Arestat™, we are
developing an internal portfolio of proprietary products in
diabetes and other indications, as well as working with leading
pharmaceutical and biotechnology companies to deliver therapeutic
products. The Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our
website, www.arecor.com
-
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRAUNRARSVUKUUR
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Dec 2023 to Dec 2024
